Stoke Therapeutics is a biotechnology company focused on RNA medicine to restore protein expression. They are developing antisense oligonucleotides (ASOs) to selectively restore naturally occurring protein levels. Their lead medicine, zorevunersen, is in Phase 3 for Dravet syndrome and is being developed in collaboration with Biogen. Another ASO, STK-002, is in Phase 1 for autosomal dominant optic atrophy (ADOA). Stoke also has early research in Syngap1. Their initial focus is on central nervous system and eye diseases caused by haploinsufficiency, with potential applications in other areas.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
11-50 employees